Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
about
Established and emerging targeted therapies in the myelodysplastic syndromes.Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-AnalysisOutcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapyClonal evolution in myelodysplastic syndromesMolecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.Stem and progenitor cell alterations in myelodysplastic syndromes.Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.Splicing factor mutations in MDS RARS and MDS/MPN-RS-T.Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome.
P2860
Q30245476-6F5C7672-A210-4711-A9B1-704269ABDBB8Q33436627-C4D7966F-A6DE-4D57-98F3-6A4E58F8B5E7Q33914183-B5BA5FEA-7830-4871-B717-2C59795B3C4FQ34555597-87874EB1-1D48-49F6-8032-CE1675762BA6Q37482287-276E8071-873F-4A79-AC63-907F6990B42AQ38761791-7BEBF6EC-DBF1-4ABF-8AC4-B81DF64C4655Q38857091-244F96C2-5500-4D59-A7AF-56F0A05A25E4Q39155501-70EE55A4-2B66-489D-B7CC-085E5EE91101Q39279998-E216466E-630C-4C9F-945A-59D3FFE3733DQ48252834-4D92BBD1-9D5F-4629-A53E-440CB7B739F4Q52777531-54B67EC5-B307-44A4-9B20-0A54B9F6D648Q55009819-CDF47C51-C97D-41C7-9C69-8BA8FDF6E997
P2860
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of lenalidomide treatme ...... syndromes without 5q deletion
@en
Effect of lenalidomide treatme ...... syndromes without 5q deletion.
@nl
type
label
Effect of lenalidomide treatme ...... syndromes without 5q deletion
@en
Effect of lenalidomide treatme ...... syndromes without 5q deletion.
@nl
prefLabel
Effect of lenalidomide treatme ...... syndromes without 5q deletion
@en
Effect of lenalidomide treatme ...... syndromes without 5q deletion.
@nl
P2093
P2860
P50
P1433
P1476
Effect of lenalidomide treatme ...... syndromes without 5q deletion
@en
P2093
Aline Renneville
Andrea Toma
Anna Raimbault
Aspasia Stamatoullas
Christian Rose
Florent Dumont
François Dreyfus
Groupe Francophone des Myélodysplasies
Jacques Delaunay
Julie Lejeune
P2860
P304
P356
10.1182/BLOOD-2015-04-640128
P407
P50
P577
2015-12-01T00:00:00Z